EUVIMEDEUVIMED entdecken
Crossref

Cascade Catalytic Nanozyme Amplifies Ferroptosis Immunotherapy in Bladder Cancer

Hongbo Luo iD, Xiaolong Liu, Yang Du iD

Journal of Biomedical Materials Research Part A · 2026

DOI: 10.1002/jbm.a.70164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, 2026. Verfasst von Hongbo Luo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Ferroptosis, Immunotherapy, Naphthoquinones. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have shown limited efficacy in bladder cancer due to the immunosuppressive tumor microenvironment. To address this challenge, we developed a β‐lapachone‐loaded iron‐based carbon nanozyme (C‐MIL@Lapa) that synergistically induces ferroptosis and immunogenic cell death (ICD). Carbonized MIL‐100(Fe) (C‐MIL) serves as both a drug carrier and a nanozyme with dual peroxidase and glutathione oxidase activities. In tumor cells, β‐lapachone generates endogenous H 2 O 2 via NQO1‐mediated redox cycling, which is then converted into cytotoxic hydroxyl radicals by C‐MIL. This cascade reaction causes glutathione depletion and lipid peroxidation, leading to ferroptosis. Meanwhile, ferroptotic cell death releases damage‐associated molecular patterns that trigger ICD, activating dendritic cells and CD8 + T cell‐mediated antitumor immunity. In vitro and in vivo results demonstrated that C‐MIL@Lapa significantly inhibited bladder cancer growth and remodeled the tumor immune microenvironment. This work provides a nanozyme‐based strategy for synergistic ferroptosis‐immunotherapy of bladder cancer with promising clinical potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsFerroptosisImmunotherapyNaphthoquinonesAnimalsHumansCell Line, TumorMiceCatalysisFemaleTumor MicroenvironmentIron

Stichwörter der Autor:innen

bladder cancerferroptosisimmunotherapynanozyme

Substanzen

Naphthoquinonesbeta-lapachoneIron

Autor:innen und Institutionen

  • Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
  • Department of Urology, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingshan, Hubei Province, China.

ORCID-Profile: Hongbo Luo, Yang Du

Zitieren

APA

Luo, H., Liu, X., & Du, Y. (2026). Cascade Catalytic Nanozyme Amplifies Ferroptosis Immunotherapy in Bladder Cancer. Journal of Biomedical Materials Research Part A. https://doi.org/10.1002/jbm.a.70164

Vancouver

Luo H, Liu X, Du Y. Cascade Catalytic Nanozyme Amplifies Ferroptosis Immunotherapy in Bladder Cancer. Journal of Biomedical Materials Research Part A. 2026. doi:10.1002/jbm.a.70164

BibTeX
@article{Luo2026,
  author = {Luo, Hongbo and Liu, Xiaolong and Du, Yang},
  title = {Cascade Catalytic Nanozyme Amplifies Ferroptosis Immunotherapy in Bladder Cancer},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2026},
  doi = {10.1002/jbm.a.70164}
}
Kostenlos starten →